plerixafor has been researched along with Graft-Versus-Host Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, MH; Gao, SJ; Gu, XY; Hu, Z; Meng, XD; Su, L; Wang, X; Yang, YG; Zou, J | 1 |
| Agarwal, S; Bakane, A; Kharya, G; Rauthan, A | 1 |
| Gao, H; Huang, XJ; Liang, S; Liu, J; Liu, R; Wu, N; Xu, LP; Zhang, XH | 1 |
| Couban, S; Eaves, CJ; Foley, R; Ivison, S; Jones, D; Kariminia, A; Schultz, KR; Wong, PPC | 1 |
| Huang, Y; Ildstad, ST; Xu, H; Zhu, Z | 1 |
| Bahceci, E; Bolan, CD; Calandra, G; Childs, RW; Cook, L; Dunbar, C; Geller, N; Joo, J; Khuu, HM; Kurlander, R; Leitman, SF; Lundqvist, A; McCoy, JP; Ramos, C; Read, EJ; Smith, AL; Takahashi, Y; Tawab, A; Wong, S | 1 |
| Bagger, FO; Blazar, BR; Boyle, GM; Don, AL; Hill, GR; Kuns, RD; Le Texier, L; Leveque, L; Lineburg, KE; MacDonald, KP; Markey, KA; Morris, H; Vuckovic, S; Zhang, P | 1 |
| Assanelli, A; Bellio, L; Ciceri, F; Coppola, M; Corti, C; De Freitas, T; Gattillo, S; Malabarba, L; Malato, S; Marktel, S; Milani, R; Rizzo, L | 1 |
| Arbez, J; Couturier, M; Gaugler, B; Lamarthée, B; Malard, F; Mohty, M; Saas, P | 1 |
| Bertaina, A; Locatelli, F; Lucarelli, B; Mingari, MC; Montaldo, E; Moretta, F; Moretta, L; Petronelli, F; Pitisci, A | 1 |
| Abboud, CN; Cashen, AF; Christ, S; Deych, E; DiPersio, JF; Eades, W; Fiala, M; Lopez, S; McFarland, K; Mir, FA; Rettig, MP; Schroeder, MA; Shannon, W; Shao, J; Stockerl-Goldstein, K; Trinkaus, K; Uy, GL; Vij, R; Westervelt, P; Yu, J | 1 |
| DiPersio, JF; Pusic, I | 1 |
1 review(s) available for plerixafor and Graft-Versus-Host Disease
| Article | Year |
|---|---|
The use of growth factors in hematopoietic stem cell transplantation.
Topics: Animals; Benzylamines; Clinical Trials as Topic; Cyclams; Cytokines; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2008 |
2 trial(s) available for plerixafor and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Topics: Adult; Aged; Allografts; Antigens, CD34; Benzylamines; Blood Cell Count; Carcinoma, Renal Cell; Colony-Forming Units Assay; Cyclams; Drug Synergism; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Kidney Neoplasms; Lenograstim; Leukapheresis; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Pain; Parents; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Siblings; Treatment Outcome | 2015 |
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.
Topics: Administration, Intravenous; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Peripheral Blood Stem Cells; Tissue Donors; Transcriptome; Transplantation, Homologous | 2017 |
9 other study(ies) available for plerixafor and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD.
Topics: Animals; Benzylamines; Chimerism; Cyclams; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Stem Cells; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2021 |
Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.
Topics: Anemia, Sickle Cell; Benzylamines; Cyclams; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Transplantation Conditioning | 2021 |
γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.
Topics: Adolescent; Adult; Animals; Benzylamines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Chemokine CXCL12; Chemotaxis, Leukocyte; Coculture Techniques; Cyclams; Disease Models, Animal; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Intraepithelial Lymphocytes; Male; Mice, Inbred NOD; Middle Aged; Receptors, Antigen, T-Cell, alpha-beta; Receptors, CXCR4; Signal Transduction; Transplantation, Homologous; Young Adult | 2021 |
Plerixafor effectively mobilizes CD56
Topics: Adolescent; Adult; Allografts; Benzylamines; CD56 Antigen; Cyclams; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Killer Cells, Natural; Middle Aged; Young Adult | 2018 |
FL/GCSF/AMD3100-mobilized Hematopoietic Stem Cells Induce Mixed Chimerism With Nonmyeloablative Conditioning and Transplantation Tolerance.
Topics: Animals; Benzylamines; Cell Survival; Cyclams; Drug Synergism; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Inbred C57BL; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation Tolerance; Transplantation, Homologous | 2019 |
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Topics: Animals; Antigens, CD; Benzylamines; CD4-Positive T-Lymphocytes; Cyclams; Cytokines; Forkhead Transcription Factors; Gene Expression Regulation; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Immunophenotyping; Lymphocyte Culture Test, Mixed; Lymphopoiesis; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Radiation Chimera; Receptors, CXCR4; Specific Pathogen-Free Organisms; T-Lymphocyte Subsets | 2013 |
Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.
Topics: Animals; Benzylamines; Cell Proliferation; Cyclams; Flow Cytometry; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Interleukin-10; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Receptors, CXCR4; Signal Transduction; Stem Cell Transplantation; T-Lymphocytes; T-Lymphocytes, Regulatory; Transcriptome | 2014 |
Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease.
Topics: Animals; Antigens, Ly; Benzylamines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclams; Dendritic Cells; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Membrane Proteins; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-kit; Receptors, CCR6; Spleen | 2015 |
The generation of human innate lymphoid cells is influenced by the source of hematopoietic stem cells and by the use of G-CSF.
Topics: Antigens, CD34; Benzylamines; Bone Marrow Cells; CD56 Antigen; Cell Count; Cyclams; Fetal Blood; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunity, Innate; Lymphocytes; Lymphopoiesis; NK Cell Lectin-Like Receptor Subfamily B; Phenotype | 2016 |